Safety and efficacy of dietary agmatine sulfate in lumbar disc-associated radiculopathy. An open-label, dose-escalating study followed by a randomized, double-blind, placebo-controlled trial

Pain Medicine

Volumn 11, Issue 3, 2010, Pages 356-368

  Keynan, Ory ^a   Mirovsky, Yigal ^b   Dekel, Samuel ^a   Gilad, Varda H ^c   Gilad, Gad M ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c G and V Gilad Ltd   (Israel)

Author keywords

Agmatine; Back pain; Clinical trial; Dietary ingredient; Sciatica; Spine

Indexed keywords

AGMATINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HUMAN; LUMBAR DISK HERNIA; MALE; MCGILL PAIN QUESTIONNAIRE; MORNING DOSAGE; MYELORADICULOPATHY; NAUSEA; OPEN STUDY; OSWESTRY DISABILITY INDEX; PAIN ASSESSMENT; PHYSIOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORIMOTOR FUNCTION; SHORT FORM 36; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

EID: 77950973481     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2010.00808.x     Document Type: Article

References (70)

1. Weber H. Spine update: The natural history of disc herniation and the influence of intervention. Spine 1994, 19:2234-8.
2. Frymoyer JW. Back pain and sciatica. N Engl J Med 1988, 318:291-300.
3. Weber H. Lumbar disc herniation. A controlled prospective study with ten years of observation. Spine 1983, 8:131-40.
4. Hofstee DJ, Gijtenbeek JMM, Hoogland PH. Westeinde sciatica trial: Randomized controlled study of bed rest and physiotherapy for acute sciatica. J Neurosurg (Spine 1) 2002, 96:45-9.
5. Vroomen PC, de Krom MC, Knottnerus JA. Predicting the outcome of sciatica at short-term follow-up. Br J Gen Pract 2002, 52:119-23.
6. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009, 13:185-90.
7. Rydevik B, Brown MD, Lundborg G. Pathoanatomy and Pathophysiology of nerve root compression. Spine 1984, 9:7-15.
8. Hoke A. Neuroprotection in the peripheral nervous system. Rationale for more effective therapies. Arch Neurol 2006, 63:1681-5.
9. Cajal SRY. Degeneration and Regeneration of the Nervous System 1928, Translated Ed. May RM, New York, Oxford University Press
10. Kobayashi S, Uchida K, Yayama T. Motor neuron involvement in experimental lumbar nerve root compression. A light and electron microscopy study. Spine 2007, 32:627-34.
11. Sekiguchi Y, Kikuchi S, Meyers RR, Campana WM. Erythropoietin inhibits spinal neuronal apoptosis and pain following nerve root crush. Spine 2003, 28:2577-84.
12. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984, 53:749-90.
13. Bauza T, Blaise A, Daumas F, Cabanis JC. Determination of biogenic amines and their precursor amino acids in wines of the Vallee du Rhone by high-performance liquid chromatography with precolumn derivatization and fluorimetric detection. J Chromat 1995, 707:373-9.
14. Izquierdopulido M, Hernandezjover T, Marinefont A, Vidalcarou MC. Biogenic amines in European bears. J Agric Food Chem 1996, 44:3159-63.
15. Morris B. Bio-functional legumes with nutraceutical, pharmaceutical, and industrial uses. Economic Botany 2003, 57:254-61.
16. Gloria MB, Tavares-Neto J, Labanca RA, Caevalho MS. Influence of cultivar and germination on bioactive amines in soybeans. J Agric Food Chem 2005, 53:7480-5.
17. Kawabata T, Obshima H, Ino M. Occurrence of methylguanidine and agmatine in foods. IARC Sci Publ 1978, 19:414-23.
18. Ruiz-Capillas C, Moral A. Formation of biogenic amines in bulk-stored chilled hake (Merluccius merluccius L.) packed under atmospheres. J Food Prot 2001, 64:1045-50.
19. Swanson KS, Grieshop CM, Flickinger EA. Fructooligosaccharides and Lactobacillus acidophilus modify bowel function and protein catabolites excreted by healthy humans. J Nutr 2002, 132:3042-50.
20. Molderings GJ, Heinen A, Menzel S. Gastrointestinal uptake of agmatine: Distribution in tissues and organs and pathophysiologic relevance. Ann NY Acad Sci 2003, 1009:44-51.
21. Piletz JE, May PJ, Wang G, Zhu H. Agmatine crosses the blood-brain barrier. Ann NY Acad Sci 2003, 1009:64-74.
22. Raasch W, Schafer U, Chun J, Dominiak P. Biological significance of agmatine, and endogenous ligand at imidazoline binding sites. J Pharmacol 2001, 133:755-80.
23. Gilad GM, Salame K, Rabey JM, Gilad VH. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci 1995, 58:PL41-6.
24. Gilad GM, Gilad VH. Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats. Neurosci Lett 2000, 296:97-100.
25. Fairbanks CA, Schreiber KL, Brewer KL. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA 2000, 97:10584-9.
26. Kim JH, Yenari MA, Giffard RG. Agmatine reduces infarct area in a mouse model of transient focal ischemia and protects cultured neurons from ischemia-like injury. Exp Neurol 2004, 189:122-30.
27. LeBlanc MH, Feng YZ, Piletz JE. Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Soc Neurosci Online Program 2002, Abstract No: 391.11
28. Bence AK, Worthen DR, Stables JP, Crooks PA. An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Pharmacol Biochem Behav 2003, 74:771-5.
29. Berenholz L, Segal S, Gilad VH. Agmatine treatment and vein graft reconstruction enhance recovery after experimental facial nerve injury. J Peripher Nerv Syst 2005, 10:319-28.
30. Feng Y, Piletz JE, LeBlanc MH. Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res 2002, 52:606-11.
31. Kotil K, Kuscuoglu U, Kirali M. Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: A prospective randomized and placebo-control trial. J Neurosurg Spine 2006, 4:392-9.
32. Zomkowski AD, Hammes L, Lin J. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 2002, 13:387-91.
33. Lavinsky D, Arteni NS, Netto CA. Agmatine induces anxiolysis in the elevated plus maze task in adult rat. Behv Brain Res 2003, 14:19-24.
34. Gilad GM, Gilad VH, Rabey JM. Arginine and ornithine decarboxylation in rodent brain; coincidental changes during development and after ischemia. Neurosci Lett 1996, 216:33-6.
35. Loring RH. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br J Pharmacol 1990, 99:207-11.
36. Pinthong D, Hussain JF, Kendall DA, Wilson VG. Comparison of the interaction of agmatine and crude methanolic extracts of bovine lung and brain with alpha(2)-adrenergic binding sites. Br J Pharmacol 1995, 115:689-95.
37. Reis DJ, Regunathan S. Agmatine: A novel neurotransmitter? Adv Pharmacol 1998, 42:645-9.
38. Yang XC, Reis DJ. Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Therap 1999, 288:544-9.
39. Shepherd RM, Hashmi MN, Kane C, Squires PE, Dunne MJ. Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: Implications for stimulus-response coupling of insulin release. Br J Pharmacol 1996, 119:911-16.
40. Xie-Chuan W, Xiao-Dan G, Jian-Quan Z, Jin L. Agmatine blocked voltage-gated calcium channel in cultured rat hippocampal neurons. Acta Pharmacol Sin 2003, 24:746-50.
41. Komori Y, Guillermo CW, Fukuto JM. Inhibition of purified nitric oxide synthase from rat cerebellum and macrophage by l-arginine analogs. Arch Biochem Biophys 1994, 315:213-18.
42. Auguet M, Viossat I, Marin JG, Chabrier PE. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol 1995, 69:285-7.
43. Galea E, Regunathan S, Eliopoulus V, Feinstein DL, Reis DJ. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996, 316:247-9.
44. Gilad GM, Wollman Y, Iaina A. Metabolism of agmatine into urea but not into nitric oxide in rat brain. NeuroReport 1996, 7:1730-2.
45. Murayama T, Tsai S-C, Adamik R, Moss J, Vaughan M. Effects of temperature on ADP-ribosylation factor stimulation of cholera toxin activity. Biochem 1993, 32:561-7.
46. Yang MZ, Mun CH, Choi YJ. Agmatine inhibits matrix metalloproteinase-9 via endothelial nitric oxide synthase in cerebral endothelial cells. Neurol Res 2007, 29:749-54.
47. Kawasaki Y, Xu ZZ, Wang X. Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain. Nat Med 2008, 14(3):331-6.
48. Dang AB, Tay BK, Kim HT. Inhibition of MMP2/MMp9 after spinal cord trauma reduces apoptosis. Spine 2008, 33:E576-9.
49. Vlassara H, Bocala R, Striker L. Pathogenic effects of advanced glycosylation: Biochemical, biological, and clinical implications for diabetes and aging. Lab Invest 1994, 70:138-51.
50. Marx M, Trittenwein G, Aufricht C, Hoeger H, Lubec B. Agmatine and spermidine reduce collagen accumulation in kidneys of diabetic db/db mice. Nephron 1995, 69:155-8.
51. Prieto EJ, Hopson L, Bradley LA. The language of low back pain: Factor structure of the McGill pain questionnaire. Pain 1980, 8:11-19.
52. Bombardier C. Outcome assessments in the evaluation of treatment of spinal disorders: Summary and general recommendations. Spine 2000, 25:3100-3.
53. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-83.
54. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang H, Lazarus JM. Quality-of-life evaluation using Short Form 36: Comparison in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2000, 35:293-300.
55. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 2001, 12:2797-806.
56. Sachs BL, Vanharanta H, Spivey MA. Dallas discogram description: A new classification of CT/discography in low back disorders. Spine 1987, 12:287-94.
57. Gibson JN, Grant IC, Waddell G. The Cochran review of surgery for lumbar disc prolapse and degenerative lumbar spondylosis. Spine 1999, 24:1820-32.
58. Weinstein JN, Lurie JD, Tosteson TD. Surgical vs nonoperative treatment for lumbar disk herniation. The Spine Patient Outcomes Research Trial (SPORT): Observational Cohort. JAMA 2006, 296:2451-9.
59. Weinstein JN, Tosteson TD, Lurie JD. Surgical vs nonoperative treatment for lumbar disk herniation. The Spine Patient Outcomes Research Trial (SPORT): A randomized trial. JAMA 2006, 296:2441-50.
60. Thomas KC, Fisher CG, Boyd M. Outcome evaluation of surgical and nonsurgical management of lumbar disc protrusion causing radiculopathy. Spine 2007, 32:1414-22.
61. Tubach F, Beaute J. Natural history and prognostic indicators of sciatica. J Clin Epidemiol 2004, 57:174-9.
62. Weinstein JN, Lurie JD, Tosteson TD. Surgical versus nonoperative treatment for lumbar disc herniation: Four-year results for the spine patient outcomes research trial (SPORT). Spine 2008, 33:2789-800.
63. McCormick PC. The Spine Patient Outcomes Research Trial results for lumbar disc herniation: A critical review. J Neurosurg Spine 2007, 6:513-20.
64. Pearson AM, Blood EA, Frymoyer JW. SPORT lumbar intervertebral disk herniation and back pain. Does treatment, location, or morphology matter. Spine 2008, 33:428-35.
65. Koes BW, Bouter LM, van der Heijden GJ. Methodological quality of randomized clinical trials on treatment efficacy on low back pain. Spine 1995, 20:228-35.
66. de la Fuente-Fernandez R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet Neurol 2002, 1:85-91.
67. Haenisch B, von Kügelgen I, Bönisch H. Regulatory mechanisms underlying agmatine homeostasis in humans. Am J Physiol Gastrointest Liver Physiol 2008, 295:G1104-10.
68. Kolesnikov Y, Jain S, Pasternak GW. Modulation of opioid analgesia by agmatine. Eur J Pharmacol 1996, 296:17-22.
69. Ji RR, Strichartz G. Cell signaling and the genesis of neuropathic pain. Sci STKE 2004
70. Cernak I. Recent advances in neuroprotection for treating traumatic brain injury. Expert Opin Investig Drugs 2006, 15:1371-81.